Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10474924 | 0.93 | TYMP (0.59) | TYMPMAPK1HPGD | |
| SCHEMBL12400915 | 0.93 | TYMP (0.59) | TYMPMAPK1HPGD | |
| SCHEMBL16102563 | 0.91 | TYMP (0.58) | TYMPMAPK1HPGD | |
| SCHEMBL10474814 | 0.90 | TYMP (0.56) | TYMPMAPK1HPGD | |
| SCHEMBL10474817 | 0.86 | TYMP (0.56) | TYMPMAPK1HPGD | |
| SCHEMBL10475702 | 0.86 | TYMP (0.52) | TYMPMAPK1HPGD | |
| SCHEMBL22193320 | 0.85 | TYMP (0.60) | TYMPMAPK1HPGDALDH1A1 | |
| SCHEMBL12859844 | 0.85 | TYMP (0.53) | TYMPMAPK1HPGD | |
| SCHEMBL10475716 | 0.85 | TYMP (0.51) | TYMPMAPK1HPGD | |
| SCHEMBL10474794 | 0.84 | TYMP (0.50) | TYMPMAPK1HPGDMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | KUMAR, RAKESH (CA) | 2010-05-27 | — | — | US | disclosed |
| US-7589077-B2 | such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus | Kumar, Rakesh (CA) | 2009-09-15 | — | — | US | disclosed |
| US-7589077-B2 | such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus | Kumar, Rakesh (CA) | 2009-09-15 | — | — | US | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| WO-2007106561-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | ALT SOLUTIONS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | PNP, ENTPD5, ADA | TYMP 9/4885MAPK1 3332/4885HPGD 1280/4885 |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | TERT, POLRMT, RNASE1 | TYMP 6/4885MAPK1 3751/4885HPGD 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.